Article

Costs for glaucoma interventions

Author(s):

Doug Katsev, MD

How affordable are glaucoma interventions in developed and developing countries? Doug Katsev, MD, takes a look.

 

How affordable are glaucoma interventions in developed and developing countries? Doug Katsev, MD, takes a look.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) EyeCon 2025: Oluwatosin U. Smith, MD, previews a program of collaborative care and practical learning
(Image credit: Ophthalmology Times) Accelerating eye health innovation through CCOI – Stanford Summit
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
Related Content
Nicox releases topline data from phase 3 Denali trial of NCX 470 in open-angle glaucoma or ocular hypertension patients
August 22nd 2025

Nicox releases topline data from phase 3 Denali trial of NCX 470 in open-angle glaucoma or ocular hypertension patients

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
August 22nd 2025

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

(Image credit: AdobeStock/InkInvent) FDA clears path for US IDE study of Myra Vision’s titratable glaucoma therapy
August 22nd 2025

FDA clears path for US IDE study of Myra Vision’s titratable glaucoma therapy

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
August 22nd 2025

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

PolyActiva enrolls first patient in phase 2b clinical trial of PA5108 ocular implant
August 22nd 2025

PolyActiva enrolls first patient in phase 2b clinical trial of PA5108 ocular implant

Kowa initiates phase 3 safety trial of NCX 470 in Japan
August 22nd 2025

Kowa initiates phase 3 safety trial of NCX 470 in Japan

© 2025 MJH Life Sciences

All rights reserved.